Bladder cancer

No Pathway Network information available for Bladder cancer

Pathways in the Bladder cancer SuperPath

#	Name	Source	Genes
1	Bladder cancer	WikiPathways	ARAF BRAF CCND1 CDH1 CDK4 CDKN1A CDKN2A CXCL8 DAPK1 DAPK2 DAPK3 E2F1 EGF EGFR ERBB2 FGFR3 HBEGF HRAS KRAS MAP2K1 MAP2K2 MAPK1 MDM2 MMP1 MMP2 MMP9 MYC NRAS PIK3R1 PIK3R2 RAF1 RASSF1 RB1 RPS6KA5 SRC THBS1 TP53 TYMP UPK3A VEGFA (see all 40) (see less)

Ordered by rank within the SuperPath, via the multiplicity of each gene in the constituent pathways

#	Symbol	Description	Category	# Related Pathways
1	CDH1	Cadherin 1	Protein Coding	1
2	RPS6KA5	Ribosomal Protein S6 Kinase A5	Protein Coding	1
3	VEGFA	Vascular Endothelial Growth Factor A	Protein Coding	1
4	TP53	Tumor Protein P53	Protein Coding	1
5	THBS1	Thrombospondin 1	Protein Coding	1
6	BRAF	B-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
7	SRC	SRC Proto-Oncogene, Non-Receptor Tyrosine Kinase	Protein Coding	1
8	CCND1	Cyclin D1	Protein Coding	1
9	RB1	RB Transcriptional Corepressor 1	Protein Coding	1
10	RAF1	Raf-1 Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
11	MAP2K2	Mitogen-Activated Protein Kinase Kinase 2	Protein Coding	1
12	MAP2K1	Mitogen-Activated Protein Kinase Kinase 1	Protein Coding	1
13	MAPK1	Mitogen-Activated Protein Kinase 1	Protein Coding	1
14	PIK3R2	Phosphoinositide-3-Kinase Regulatory Subunit 2	Protein Coding	1
15	PIK3R1	Phosphoinositide-3-Kinase Regulatory Subunit 1	Protein Coding	1
16	NRAS	NRAS Proto-Oncogene, GTPase	Protein Coding	1
17	MYC	MYC Proto-Oncogene, BHLH Transcription Factor	Protein Coding	1
18	MMP9	Matrix Metallopeptidase 9	Protein Coding	1
19	MMP2	Matrix Metallopeptidase 2	Protein Coding	1
20	MMP1	Matrix Metallopeptidase 1	Protein Coding	1
21	MDM2	MDM2 Proto-Oncogene	Protein Coding	1
22	KRAS	KRAS Proto-Oncogene, GTPase	Protein Coding	1
23	ARAF	A-Raf Proto-Oncogene, Serine/Threonine Kinase	Protein Coding	1
24	CXCL8	C-X-C Motif Chemokine Ligand 8	Protein Coding	1
25	HRAS	HRas Proto-Oncogene, GTPase	Protein Coding	1
26	DAPK2	Death Associated Protein Kinase 2	Protein Coding	1
27	FGFR3	Fibroblast Growth Factor Receptor 3	Protein Coding	1
28	ERBB2	Erb-B2 Receptor Tyrosine Kinase 2	Protein Coding	1
29	EGFR	Epidermal Growth Factor Receptor	Protein Coding	1
30	EGF	Epidermal Growth Factor	Protein Coding	1
31	TYMP	Thymidine Phosphorylase	Protein Coding	1
32	E2F1	E2F Transcription Factor 1	Protein Coding	1
33	HBEGF	Heparin Binding EGF Like Growth Factor	Protein Coding	1
34	DAPK1	Death Associated Protein Kinase 1	Protein Coding	1
35	RASSF1	Ras Association Domain Family Member 1	Protein Coding	1
36	CDKN2A	Cyclin Dependent Kinase Inhibitor 2A	Protein Coding	1
37	CDKN1A	Cyclin Dependent Kinase Inhibitor 1A	Protein Coding	1
38	CDK4	Cyclin Dependent Kinase 4	Protein Coding	1
39	DAPK3	Death Associated Protein Kinase 3	Protein Coding	1
40	UPK3A	Uroplakin 3A	Protein Coding	1

Disorders associated with Bladder cancer SuperPath

according to GeneCards Suite gene sharing

#	Disorder	Type	Genes	Score
1	Colorectal cancer	Enrichment	BRAF, CCND1, CDH1, ERBB2, FGFR3, NRAS, PIK3R1, SRC, TP53	16.00
2	Lung cancer susceptibility 3	Enrichment	BRAF, EGFR, ERBB2, KRAS, RB1, TP53	16.00
3	Rasopathy	Enrichment	BRAF, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1	16.00
4	Lip and oral cavity carcinoma	Enrichment	BRAF, CDKN2A, EGFR, HRAS, RB1, TP53	16.00
5	Noonan syndrome 1	Enrichment	BRAF, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1	11.81
6	Bladder cancer	Enrichment	CDKN1A, CDKN2A, EGFR, ERBB2, FGFR3, HRAS, KRAS, RB1, TP53	11.51
7	Noonan syndrome and noonan-related syndrome	Enrichment	BRAF, HRAS, KRAS, MAP2K1, MAP2K2, NRAS, RAF1	11.09
8	Lung non-small cell carcinoma	Enrichment	BRAF, EGFR, ERBB2, HRAS, KRAS, MAP2K1, NRAS	10.94
9	Cardiofaciocutaneous syndrome 1	Enrichment	BRAF, KRAS, MAP2K1, MAP2K2	10.07
10	Cardiofaciocutaneous syndrome	Enrichment	BRAF, KRAS, MAP2K1, MAP2K2	10.07
11	Lung squamous cell carcinoma	Enrichment	CDKN2A, EGFR, FGFR3, KRAS	9.01
12	Nevus, epidermal	Enrichment	FGFR3, HRAS, KRAS, NRAS	8.64
13	Gastric cancer	Enrichment	CDH1, CDK4, CDKN2A, ERBB2, KRAS, TP53	8.60
14	Melanocytic nevus syndrome, congenital	Enrichment	BRAF, HRAS, NRAS, RAF1	8.34
15	Myeloma, multiple	Enrichment	BRAF, CCND1, FGFR3, KRAS, PIK3R2, TP53	7.89
16	Ovarian cancer	Enrichment	CDH1, CDKN2A, EGFR, ERBB2, KRAS, RB1, TP53	7.81
17	Langerhans cell histiocytosis	Enrichment	BRAF, MAP2K1, NRAS	7.62
18	Schimmelpenning-feuerstein-mims syndrome	Enrichment	HRAS, KRAS, NRAS	7.02
19	Li-fraumeni syndrome	Enrichment	CDKN2A, MDM2, TP53	6.33
20	Thyroid cancer, nonmedullary, 2	Enrichment	BRAF, HRAS, NRAS	6.08
21	Noonan syndrome 3	Enrichment	HRAS, KRAS, RAF1	6.08
22	Gallbladder cancer	Enrichment	BRAF, KRAS, TP53	6.08
23	Pilomyxoid astrocytoma	Enrichment	BRAF, KRAS, RAF1	6.08
24	Follicular thyroid carcinoma	Enrichment	BRAF, HRAS, NRAS	6.08
25	Differentiated thyroid carcinoma	Enrichment	BRAF, HRAS, KRAS, NRAS	5.84
26	Lung cancer	Enrichment	BRAF, EGFR, ERBB2, KRAS	5.66
27	Inherited cancer-predisposing syndrome	Enrichment	CDH1, CDK4, CDKN2A, EGFR, RB1, TP53	5.65
28	Cervical cancer	Enrichment	FGFR3, TP53	5.07
29	Ras-associated autoimmune leukoproliferative disorder	Enrichment	KRAS, NRAS	5.07
30	Cervix carcinoma	Enrichment	FGFR3, TP53	5.07
31	Gliosarcoma	Enrichment	EGFR, FGFR3, TP53	4.89
32	Melanoma, cutaneous malignant 1	Enrichment	BRAF, CDK4, CDKN2A	4.80
33	Giant cell glioblastoma	Enrichment	EGFR, FGFR3, TP53	4.80
34	Arteriovenous malformations of the brain	Enrichment	BRAF, EGFR, KRAS	4.65
35	Osteogenic sarcoma	Enrichment	RB1, TP53	4.60
36	Large congenital melanocytic nevus	Enrichment	HRAS, NRAS	4.60
37	Dedifferentiated liposarcoma	Enrichment	CDK4, MDM2	4.60
38	Squamous cell carcinoma	Enrichment	RB1, TP53	4.60
39	Bone osteosarcoma	Enrichment	RB1, TP53	4.60
40	Spermatocytoma	Enrichment	FGFR3, HRAS	4.60
41	Well-differentiated liposarcoma	Enrichment	CDK4, MDM2	4.60
42	Diffuse gastric and lobular breast cancer syndrome	Enrichment	CDH1, KRAS	4.30
43	Small cell cancer of the lung	Enrichment	RB1, TP53	4.30
44	Thyroid cancer, nonmedullary, 1	Enrichment	BRAF, TP53	4.30
45	Lung sarcomatoid carcinoma	Enrichment	KRAS, TP53	4.30
46	Chronic myelogenous leukemia, bcr-abl1 positive	Enrichment	KRAS, NRAS	4.30
47	Noonan syndrome with multiple lentigines	Enrichment	BRAF, RAF1	4.30
48	Pancreatic cancer	Enrichment	CDKN2A, KRAS, TP53	4.28
49	Adrenocortical carcinoma	Enrichment	CDKN2A, TP53	3.90
50	Breast adenocarcinoma	Enrichment	KRAS, TP53	3.90
51	Squamous cell carcinoma, head and neck	Enrichment	EGFR, TP53	3.75
52	Capillary malformation-arteriovenous malformation 1	Enrichment	KRAS, MAP2K1	3.75
53	Leukemia, chronic myeloid	Enrichment	KRAS, NRAS	3.75
54	B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)	Enrichment	CDKN2A, TP53	3.75
55	Leukemia, acute myeloid	Enrichment	KRAS, NRAS, TP53	3.66
56	Glioma susceptibility 1	Enrichment	ERBB2, TP53	3.63
57	Lymphoma, non-hodgkin, familial	Enrichment	BRAF, TP53	3.63
58	Hereditary breast carcinoma	Enrichment	CDH1, KRAS, TP53	3.54
59	Arteriovenous malformation	Enrichment	HRAS, MAP2K1	3.52
60	Adult hepatocellular carcinoma	Enrichment	EGF, TP53	3.52
61	Primary hyperaldosteronism	Enrichment	BRAF, TP53	3.52
62	Leukemia, chronic lymphocytic	Enrichment	CCND1, TP53	3.42
63	Myopathy, x-linked, with excessive autophagy	Enrichment	HRAS, MAP2K1	3.42
64	Melanoma	Enrichment	BRAF, CDKN2A	3.42
65	Juvenile myelomonocytic leukemia	Enrichment	KRAS, NRAS	3.26
66	Renal hypodysplasia/aplasia 3	Enrichment	FGFR3, UPK3A	3.26
67	Rhabdomyosarcoma	Enrichment	HRAS, TP53	3.00
68	Breast cancer	Enrichment	CDH1, KRAS, TP53	2.86
69	Diffuse large b-cell lymphoma	Enrichment	BRAF, TP53	2.85
70	Hepatoblastoma	Enrichment	FGFR3, TP53	2.76
71	Precursor t-cell acute lymphoblastic leukemia	Enrichment	CDKN2A, MYC	2.69
72	Hypochondroplasia	Enrichment	FGFR3	2.53
73	Paget disease, extramammary	Enrichment	ERBB2	2.53
74	Thanatophoric dysplasia, type i	Enrichment	FGFR3	2.53
75	Oculoectodermal syndrome	Enrichment	KRAS	2.53
76	Muenke syndrome	Enrichment	FGFR3	2.53
77	Pallister-killian syndrome	Enrichment	ARAF	2.53
78	Noonan syndrome 5	Enrichment	RAF1	2.53
79	Hypomagnesemia 4, renal	Enrichment	EGF	2.53
80	Melanoma, cutaneous malignant 3	Enrichment	CDK4	2.53
81	Melorheostosis, isolated	Enrichment	MAP2K1	2.53
82	Noonan syndrome 7	Enrichment	BRAF	2.53
83	Leopard syndrome 3	Enrichment	BRAF	2.53
84	Cardiomyopathy, dilated, 1nn	Enrichment	RAF1	2.53
85	Cardiofaciocutaneous syndrome 3	Enrichment	MAP2K1	2.53
86	Melanosis, neurocutaneous	Enrichment	NRAS	2.53
87	Thanatophoric dysplasia, type ii	Enrichment	FGFR3	2.53
88	Noonan syndrome 6	Enrichment	NRAS	2.53
89	Camptodactyly, tall stature, and hearing loss syndrome	Enrichment	FGFR3	2.53
90	Accelerated tumor formation	Enrichment	MDM2	2.53
91	Visceral neuropathy, familial, 2, autosomal recessive	Enrichment	ERBB2	2.53
92	Noonan syndrome 13	Enrichment	MAPK1	2.53
93	Lessel-kubisch syndrome	Enrichment	MDM2	2.53
94	Short syndrome	Enrichment	PIK3R1	2.53
95	Bone marrow failure syndrome 5	Enrichment	TP53	2.53
96	Papilloma of choroid plexus	Enrichment	TP53	2.53
97	Basal cell carcinoma 7	Enrichment	TP53	2.53
98	Anaplastic thyroid carcinoma	Enrichment	TP53	2.53
99	Cardiofaciocutaneous syndrome 2	Enrichment	KRAS	2.53
100	Microvascular complications of diabetes 1	Enrichment	VEGFA	2.53
101	Lymphangioma	Enrichment	BRAF	2.53
102	Crouzon syndrome with acanthosis nigricans	Enrichment	FGFR3	2.53
103	Phace association	Enrichment	BRAF	2.53
104	Melorheostosis	Enrichment	MAP2K1	2.53
105	Leopard syndrome 2	Enrichment	RAF1	2.53
106	Immunodeficiency 36 with lymphoproliferation	Enrichment	PIK3R1	2.53
107	Cardiofaciocutaneous syndrome 4	Enrichment	MAP2K2	2.53
108	Agammaglobulinemia 7, autosomal recessive	Enrichment	PIK3R1	2.53
109	Achondroplasia, severe, with developmental delay and acanthosis nigricans	Enrichment	FGFR3	2.53
110	Ductal carcinoma in situ	Enrichment	TP53	2.53
111	Thrombocytopenia 6	Enrichment	SRC	2.53
112	Trigonitis	Enrichment	RAF1	2.53
113	Thyroid gland undifferentiated carcinoma	Enrichment	TP53	2.53
114	Trilateral retinoblastoma	Enrichment	RB1	2.53
115	Small-cell carcinoma of the ovary of hypercalcemic type	Enrichment	TP53	2.53
116	Lacrimoauriculodentodigital syndrome 2	Enrichment	FGFR3	2.53
117	Cdkn2a cancer predisposition	Enrichment	CDKN2A	2.53
118	Diffuse pediatric-type high-grade glioma, h3-wildtype and idh-wildtype	Enrichment	TP53	2.53
119	Breast lobular carcinoma	Enrichment	CDH1	2.53
120	Congenital pulmonary airway malformation	Enrichment	KRAS	2.53
121	Choroid plexus cancer	Enrichment	TP53	2.53
122	Fgfr3-related chondrodysplasia	Enrichment	FGFR3	2.53
123	Syringocystadenoma papilliferum	Enrichment	BRAF	2.53
124	Camptodactyly-tall stature-scoliosis-hearing loss syndrome	Enrichment	FGFR3	2.53
125	Pleomorphic xanthoastrocytoma	Enrichment	TP53	2.53
126	Ganglioglioma	Enrichment	BRAF	2.53
127	Nongerminomatous germ cell tumor	Enrichment	BRAF	2.53
128	Phace syndrome	Enrichment	BRAF	2.53
129	Phakomatosis pigmentokeratotica	Enrichment	HRAS	2.53
130	Classic hairy cell leukemia	Enrichment	BRAF	2.53
131	Egf-related primary hypomagnesemia with intellectual disability	Enrichment	EGF	2.53
132	Serous carcinoma of the corpus uteri	Enrichment	ERBB2	2.53
133	Neurocutaneous melanocytosis	Enrichment	NRAS	2.53
134	Lung oat cell carcinoma	Enrichment	RB1	2.53
135	Prostate cancer	Enrichment	CDH1, TP53	2.49
136	Non-immune hydrops fetalis	Enrichment	HRAS, KRAS	2.43
137	Blepharocheilodontic syndrome 1	Enrichment	CDH1	2.23
138	Melanoma-astrocytoma syndrome	Enrichment	CDKN2A	2.23
139	Burkitt lymphoma	Enrichment	MYC	2.23
140	Adrenocortical carcinoma, hereditary	Enrichment	TP53	2.23
141	Costello syndrome	Enrichment	HRAS	2.23
142	Pulmonic stenosis	Enrichment	BRAF	2.23
143	Keratosis, seborrheic	Enrichment	FGFR3	2.23
144	Encephalocraniocutaneous lipomatosis	Enrichment	KRAS	2.23
145	Melanoma, cutaneous malignant 2	Enrichment	CDKN2A	2.23
146	Chromosome 13q14 deletion syndrome	Enrichment	RB1	2.23
147	Lymphoma, hodgkin, classic	Enrichment	TP53	2.23
148	Recessive dystrophic epidermolysis bullosa	Enrichment	MMP1	2.23
149	Melanoma-pancreatic cancer syndrome	Enrichment	CDKN2A	2.23
150	Congenital fibrosarcoma	Enrichment	TP53	2.23
151	Metaphyseal anadysplasia 2	Enrichment	MMP9	2.23
152	Li-fraumeni syndrome 1	Enrichment	TP53	2.23
153	Sarcoma	Enrichment	TP53	2.23
154	Hodgkin's lymphoma	Enrichment	TP53	2.23
155	Metaphyseal anadysplasia	Enrichment	MMP9	2.23
156	Familial retinoblastoma	Enrichment	RB1	2.23
157	Pleomorphic rhabdomyosarcoma	Enrichment	TP53	2.23
158	Tafro syndrome	Enrichment	MAP2K2	2.23
159	Wooly hair nevus	Enrichment	HRAS	2.23
160	Crouzon syndrome	Enrichment	FGFR3	2.05
161	Lacrimoauriculodentodigital syndrome 1	Enrichment	FGFR3	2.05
162	Achondroplasia	Enrichment	FGFR3	2.05
163	Larsen syndrome	Enrichment	FGFR3	2.05
164	Retinoblastoma	Enrichment	RB1	2.05
165	Ataxia-telangiectasia	Enrichment	BRAF	2.05
166	Multicentric osteolysis, nodulosis, and arthropathy	Enrichment	MMP2	2.05
167	Nasopharyngeal carcinoma	Enrichment	TP53	2.05
168	Congenital lipomatous overgrowth, vascular malformations, and epidermal nevi	Enrichment	PIK3R1	2.05
169	Woolly hair, autosomal recessive 3	Enrichment	RB1	2.05
170	Neonatal nephrocutaneous inflammatory syndrome	Enrichment	EGFR	2.05
171	Immunodeficiency 14a with lymphoproliferation, autosomal dominant	Enrichment	PIK3R1	2.05
172	Hypotrichosis 8	Enrichment	RB1	2.05
173	Tethered spinal cord syndrome	Enrichment	BRAF	2.05
174	High-grade b-cell lymphoma double-hit/triple-hit	Enrichment	MYC	2.05
175	Hamartoma	Enrichment	FGFR3	2.05
176	Atypical teratoid rhabdoid tumor	Enrichment	TP53	2.05
177	Testicular germ cell cancer	Enrichment	FGFR3	2.05
178	Anaplastic astrocytoma	Enrichment	TP53	2.05
179	Immunodeficiency 14	Enrichment	PIK3R1	2.05
180	Adenocarcinoma	Enrichment	TP53	2.05
181	Neonatal inflammatory skin and bowel disease	Enrichment	EGFR	2.05
182	Testicular cancer	Enrichment	FGFR3	2.05
183	Hereditary breast ovarian cancer syndrome	Enrichment	KRAS, TP53	1.94
184	Neurofibromatosis-noonan syndrome	Enrichment	MAP2K2	1.93
185	Megalencephaly-capillary malformation-polymicrogyria syndrome	Enrichment	PIK3R2	1.93
186	Chromosome 22q11.2 deletion syndrome, distal	Enrichment	MAPK1	1.93
187	Megalencephaly-polymicrogyria-polydactyly-hydrocephalus syndrome 1	Enrichment	PIK3R2	1.93
188	Saethre-chotzen syndrome	Enrichment	FGFR3	1.93
189	Barrett esophagus	Enrichment	ERBB2	1.93
190	Lynch syndrome 4	Enrichment	RB1	1.93
191	Mantle cell lymphoma	Enrichment	CCND1	1.93
192	Ciliary dyskinesia, primary, 22	Enrichment	RASSF1	1.93
193	Embryonal rhabdomyosarcoma	Enrichment	TP53	1.93
194	Craniopharyngioma	Enrichment	BRAF	1.93
195	Pilocytic astrocytoma	Enrichment	KRAS	1.93
196	Newborn respiratory distress syndrome	Enrichment	BRAF	1.93
197	Epidermolytic nevus	Enrichment	HRAS	1.93
198	Non-syndromic bicoronal craniosynostosis	Enrichment	FGFR3	1.93
199	Hemifacial hyperplasia	Enrichment	FGFR3	1.83
200	Von hippel-lindau syndrome	Enrichment	CCND1	1.83
201	Rhabdomyosarcoma 2	Enrichment	TP53	1.83
202	Lymphoma	Enrichment	TP53	1.83
203	Acute megakaryocytic leukemia	Enrichment	TP53	1.83
204	Cowden syndrome 1	Enrichment	EGFR	1.76
205	Testicular germ cell tumor	Enrichment	FGFR3	1.76
206	Wilms tumor 5	Enrichment	BRAF	1.76
207	Mitochondrial dna depletion syndrome 1	Enrichment	TYMP	1.76
208	46,xy disorder of sex development	Enrichment	FGFR3	1.76
209	Cleft lip with or without cleft palate	Enrichment	CDH1	1.76
210	Esophageal cancer	Enrichment	TP53	1.69
211	Multiple endocrine neoplasia, type i	Enrichment	CDKN1A	1.69
212	Myelofibrosis	Enrichment	SRC	1.69
213	Essential thrombocythemia	Enrichment	TP53	1.69
214	Overgrowth syndrome	Enrichment	PIK3R1	1.69
215	Dilated cardiomyopathy	Enrichment	BRAF, RAF1	1.63
216	Mitochondrial dna depletion syndrome 4b	Enrichment	TYMP	1.63
217	Cardiomyopathy, familial hypertrophic, 4	Enrichment	BRAF	1.58
218	Ventricular septal defect	Enrichment	BRAF	1.58
219	Mitochondrial neurogastrointestinal encephalomyopathy	Enrichment	TYMP	1.58
220	Familial colorectal cancer	Enrichment	TP53	1.54
221	Autosomal non-syndromic agammaglobulinemia	Enrichment	PIK3R1	1.54
222	Primary bone dysplasia	Enrichment	FGFR3	1.54
223	Leukemia, acute lymphoblastic	Enrichment	CDKN2A	1.50
224	Myelodysplastic syndrome	Enrichment	TP53	1.50
225	Osteochondrodysplasia	Enrichment	FGFR3	1.50
226	Specific learning disability	Enrichment	MAPK1	1.50
227	Protein-deficiency anemia	Enrichment	NRAS	1.42
228	Osteoporosis	Enrichment	SRC	1.39
229	Cleft lip/palate	Enrichment	CDH1	1.39
230	Wilms tumor 1	Enrichment	BRAF	1.36
231	Lynch syndrome	Enrichment	KRAS	1.36
232	Dandy-walker syndrome	Enrichment	BRAF	1.31
233	Heart, malformation of	Enrichment	MAPK1	1.29
234	Craniosynostosis	Enrichment	FGFR3	1.24
235	Endometrial cancer	Enrichment	CDH1	1.22
236	Hepatocellular carcinoma	Enrichment	TP53	1.20
237	Diamond-blackfan anemia 1	Enrichment	TP53	1.18
238	Cardiomyopathy, familial hypertrophic, 1	Enrichment	RAF1	1.16
239	Hydrops fetalis, nonimmune	Enrichment	HRAS	1.13
240	Hirschsprung disease 1	Enrichment	ERBB2	1.09
241	Connective tissue disease	Enrichment	FGFR3	1.04
242	Familial hypertrophic cardiomyopathy	Enrichment	RAF1	1.03
243	Left ventricular noncompaction	Enrichment	RAF1	1.01
244	Diamond-blackfan anemia	Enrichment	TP53	1.00
245	Thrombocytopenia	Enrichment	SRC	0.88
246	Familial isolated dilated cardiomyopathy	Enrichment	RAF1	0.84
247	Primary ovarian insufficiency	Enrichment	THBS1	0.80
248	Congenital nervous system abnormality	Enrichment	FGFR3	0.57
249	Nervous system disease	Enrichment	FGFR3	0.57
250	Autism spectrum disorder	Enrichment	MAP2K1	0.56
251	Microcephaly	Enrichment	MAPK1	0.51

¹ WikiPathways

² PubChem

³ R&D Systems

⁴ Reactome

⁵ GeneGo (Thomson Reuters)

⁶ QIAGEN

⁷ PharmGKB

⁸ Cell Signaling Technology

⁹ Sino Biological

¹⁰ Tocris

¹¹ MalaCards

Bladder cancer

Pathway Network for Bladder cancer

Member Pathways for Bladder cancer

Pathways in the Bladder cancer SuperPath

Associated Genes for Bladder cancer

Associated Disorders for Bladder cancer

Disorders associated with Bladder cancer SuperPath

STRING Interaction Network for Bladder cancer

Sources for Bladder cancer